Correction: Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes (Arthritis Research & Therapy, (2022), 24, 1, (240), 10.1186/s13075-022-02934-3)
Ueno M, Miyagawa I, Miyazaki Y, Hanami K, Fukuyo S, Kubo S, Nakayamada S, Tanaka Y (2023)
Publication Type: Journal article, Erratum
Publication year: 2023
Journal
Book Volume: 25
Article Number: 24
Journal Issue: 1
DOI: 10.1186/s13075-023-03005-x
Abstract
Following publication of the original article [1], the authors reported an error in Additional file 1: Figure S1, Panel (C), subpanel c) a description regarding the gating strategy for the activated Th17 cells. The data currently reads.
Involved external institutions
Japan (JP)How to cite
APA:
Ueno, M., Miyagawa, I., Miyazaki, Y., Hanami, K., Fukuyo, S., Kubo, S.,... Tanaka, Y. (2023). Correction: Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes (Arthritis Research & Therapy, (2022), 24, 1, (240), 10.1186/s13075-022-02934-3). Arthritis Research & Therapy, 25(1). https://dx.doi.org/10.1186/s13075-023-03005-x
MLA:
Ueno, Masanobu, et al. "Correction: Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes (Arthritis Research & Therapy, (2022), 24, 1, (240), 10.1186/s13075-022-02934-3)." Arthritis Research & Therapy 25.1 (2023).
BibTeX: Download